Investor Service Announcement no. 1/2011



To: NASDAQ OMX Copenhagen A/S
Hørsholm, Denmark, February 25, 2011




LifeCycle Pharma to Host Conference Call Announcing Annual Report 2010


LifeCycle Pharma A/S (OMX: LCP) will announce the Annual Report 2010 on Tuesday
March 1, 2011 after 5 pm CET. LCP's Management will host a conference call on
March 2, 2011, at 4:00 PM CET (Denmark); 3:00 PM GMT (London), 10:00 AM ET (New
York), 7:00 AM PT (San Francisco) to discuss the financial results.


To access the live conference call, please dial one of the following numbers:

+45 32 72 76 25 Denmark

+44 (0) 1452 555 566 UK

+1 631 510 7498 USA

Access code 48073383


Following the conference call, a recording will be available on the company's
website www.lcpharma.com. A presentation will be available on LCP's website
(under ‘Investors') one hour prior to the scheduled time of the conference
call.


For more information, please contact:



LifeCycle Pharma A/S Johnny Stilou
John Weinberg, M.D. CFO
SVP, Commercial Development and Strategic Planning Phone: + 45 2055 3817
Phone: +1 732 321 3208 Email: [email protected]
Email: [email protected]



About LifeCycle Pharma A/S (LCP)

Based in Hørsholm, Denmark, with an office in New Jersey, LCP is a specialty
pharmaceutical company. Clinical development is the core of LCP's efforts to
develop a product portfolio which includes the Company's lead product
candidate, LCP‐Tacro™, for immunosuppression, specifically organ
transplantation, and products to combat certain cardiovascular diseases. LCP
adapts new technologies on a fast commercial timetable. LCP's unique, patented
delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at
low‐scale up costs ‐ not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has a lipid lowering product,
Fenoglide®, currently on the U.S. market and a diversified near and medium term
pipeline with three clinical stage product candidates and a number of projects
in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under
the trading symbol OMX: LCP.

For further information, please visit www.lcpharma.com.

250211 LifeCycle Pharma Host Annual Report 2010 Conference Call.pdf